Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200mTakeda is to sell off a portfolio of over-the-counter and prescription drugs in the Near East, Middle East, Share XDebt-laden Takeda to sell OTC drugs in Middle East and Africa for $200mhttps://pharmaphorum.com/news/takeda-to-sell-otc-drugs-in-middle-east-and-africa-for-200m/
ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging techLA-based biotech ImaginAb has signed a multi-party agreement with pharma giants AstraZeneca, Pfizer, and Takeda, for technology that Share XImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging techhttps://pharmaphorum.com/news/imaginab-joins-with-az-pfizer-and-takeda-to-develop-tumour-imaging-tech/
Takeda breaks into top 20 largest pharmas with Shire mergerTakeda broke into the list of top 20 publicly traded innovative pharma companies after its $62 billion merger Share XTakeda breaks into top 20 largest pharmas with Shire mergerhttps://pharmaphorum.com/news/takeda-breaks-into-top-20-largest-pharmas-with-shire-merger/
Takeda eyes emerging markets asset sale to trim its debt; reportTakeda is said to be considering the sale of assets in emerging markets and western Europe to pay Share XTakeda eyes emerging markets asset sale to trim its debt; reporthttps://pharmaphorum.com/news/takeda-eyes-emerging-markets-asset-sale-to-trim-its-debt-report/
Evotec announces potential $850m R&D partnership with TakedaGermany’s Evotec has announced another high-profile R&D partnership with big pharma, beginning a multi-year R&D partnership with Takeda, Share XEvotec announces potential $850m R&D partnership with Takedahttps://pharmaphorum.com/news/evotec-announces-potential-850m-rd-partnership-with-takeda/
HAE patients get new option as NICE backs Takeda’s TakhzyroPatients in England and Wales with hereditary angioedema (HAE) should soon have a new treatment option after NICE Share XHAE patients get new option as NICE backs Takeda’s Takhzyrohttps://pharmaphorum.com/news/hae-patients-get-new-option-as-nice-backs-takedas-takhzyro/
Who will be the biggest pharma players in orphan drugs?New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with Share XWho will be the biggest pharma players in orphan drugs?https://pharmaphorum.com/views-analysis-sales-marketing/who-will-be-the-biggest-pharma-players-in-orphan-drugs/
The top pharma companies by revenue 2018New analysis from GlobalData has revealed the top 20 pharma companies by revenue for 2018, with Johnson & Share XThe top pharma companies by revenue 2018https://pharmaphorum.com/views-and-analysis/the-top-pharma-companies-by-revenue-2018/
Sosei Heptares bags another big partnership, this time with TakedaJapanese biotech Sosei’s buyout of the UK’s Heptares four years ago has rewarded it with a string of Share XSosei Heptares bags another big partnership, this time with Takedahttps://pharmaphorum.com/news/sosei-heptares-bags-another-big-partnership-this-time-with-takeda/
